Use of serd with cdk4/6 inhibitors, pi3k/mtor pathway inhibitors

Abstract

Provided is a use of SERD and CDK4 / 6 inhibitors and PI3K / mTOR pathway inhibitors. Specifically, a selective estrogen receptor down-regulator (SERD) combined with a combination of cyclin-dependent kinase 4 / 6 inhibitors (CDK4 / 6), phosphatidylinositol 3-kinase (PI3K) / Use of one or more combinations of target of rapamycin (mTOR) pathway inhibitors in the preparation of medicaments for treating breast tumors.

Description

technical field [0001] The invention belongs to the field of medicine, and relates to the use of SERD combined with one or more selected from CDK4 / 6 inhibitors and PI3K / mTOR pathway inhibitors in the preparation of drugs for treating breast tumors. Background technique [0002] Breast cancer is a malignant tumor that occurs in the glandular epithelial tissue of the breast. The classification of breast cancer is relatively complicated. According to the pathological classification, it can be divided into non-invasive breast cancer, early invasive breast cancer, invasive special breast cancer, and invasive non-special breast cancer. carcinoma, other rare and special types of breast cancer. According to molecular classification, it can be divided into luminal A type (Luminal A), luminal B type (Luminal B), epidermal growth factor receptor 2 (HER2) overexpression type, basal cell-like type, and normal breast-like type. According to epidemiological statistics, Luminal A and Lumin...

AI Technical Summary

Problems solved by technology

Currently the only SERD drug on the market is fulvestrant (AstraZeneca, AstraZeneca), but there are still some adverse reactions such as fatigue, hot flashes, joint pain, rash and loss of appetite, etc. The SERD under research is AZD-9496 ( AstraZeneca, AstraZeneca), RAD1901 (Eisai, Eisai), ZB-716 (Louisiana University, Louisiana University)

Images